EVITA TEST COMPLETE and EVITA TEST GENDER have been developed by the Danish biotech company ARCEDI in close collaboration with several Danish hospitals, the Aarhus University Hospital being the main collaborator.

EVITA TEST COMPLETE is a revolution. Expectant parents now have the opportunity to have complete peace of mind regarding the health of their unborn baby. The test is patented and is based on a simple blood test. This means that there is no risk to the baby or the mother. ARCEDI has developed the technology that makes it possible to isolate fetal cells from the mother’s blood sample. After having performed a series of clinical trials on pregnant women, ARCEDI has launched their prenatal test commercially. This enables them to offer all expectant mothers the opportunity to benefit from this unique technology.

We want to provide expectant parents with accurate information about their baby’s chromosomes, enabling them to have peace of mind, and be well-informed about the future health of their baby.


ARCEDI's Mission

Our mission is to provide pregnant women a safe, simple and accurate cell-based non-invasive prenatal diagnosis (cbNIPD) by isolating and extracting fetal calls from maternal blood for genomic analysis of the fetus.

ARCEDI's Vision

Our vision is to fundamentally transform prenatal diagnostics by making cell-free non-invasive prenatal testing (cfNIPT), chorionic villus sampling (CVS) and amniocentesis (Amnio) obsolete.

If you want to know more about ARCEDI, please visit our website.


ARCEDI has two offices in Denmark:

Tabletvej 1
DK-7100 Vejle

INCUBA, Palle Juul-Jensens Boulevard 82 DK-8200 Aarhus N

For additional information:

Lotte Hatt, Chief Scientific Officer 
Mail: loha@arcedi.com 
Phone: +45 61 71 25 57